Our Pipeline

Advancing novel product candidates for
heart disease as well as inborn errors of metabolism

We are advancing a clinical stage pipeline of novel product candidates in two key areas of energy metabolism: cardiovascular disease and inborn errors of metabolism. Our lead program, IMB-101, is currently in Phase 2 clinical development for conditions of oxygen deprivation in the heart. The initial indications we are targeting with IMB-101 are diabetic cardiomyopathy, non-obstructive hypertrophic cardiomyopathy and stable angina. Our additional product candidate, IMB-203 is designed to address the energy deficiency in patients with rare genetic mutations in mitochondrial metabolism, including those with propionic acidemia and other inborn errors of metabolism.

PROGRAM

INDICATIONS

Research/Nonclinical

Phase 1

Phase 2

Milestones

Target engagement study, results 2021/22

Results 2022

Results 2022

Ph2 start pending results of Target engagement study

PROGRAM

INDICATIONS

Research/Nonclinical

Phase 1

Phase 2

Milestones

Rare diseases of the mitochondria

Potential to be IND ready 2022

IMB-101

IMB-101 is a novel, investigational cardiac mitotrope currently in Phase 2 clinical trials for multiple cardiovascular diseases.

IMB-203

IMB-203 is a succinate prodrug designed to deliver high doses of succinate in patients with inborn errors of metabolism. IMB-203 is currently in preclinical development.